September 22, 2017
This summer, I got an email with the subject line, “Help researchers at Mass. General or the Brigham make discoveries.” Think the Boston hospitals — Massachusetts General Hospital and Brigham and Women's Hospital — were hitting me up for a check? Wrong. Not long afterward, as I was passing through a busy lobby of Mass. General, an eye-grabbing kiosk invited me to “Join us to help shape the future of healthcare.” Once again, it sure sounded like a charity appeal. But the recruiters didn't want my money. They wanted my DNA and my medical records, to help them build a massive database for research called a biobank.
July 12, 2017
The Partners Biobank has started returning research results to Biobank participants. These results are genetic variants, also called mutations, that indicate a high risk of developing certain conditions and diseases. The purpose of returning research results is to provide Biobank participants with information that could positively impact their clinical care. Results being returned are genetic variants that the American College of Medical Genetics (ACMG) defines as being actionable. This means that there are screening tests and/or preventative measures for people who have these variants.
June 20, 2017
The Spring/Summer 2017 issue of the Partners Biobank newsletter for Biobank participants has been released.
June 19, 2017
The accurate detection of tissue damage holds the potential to transform medicine through earlier detection of disease, assessment of disease progression, and real time evaluation of treatment. Dr. Mostoslavsky of the Cancer Center at Massachusetts General Hospital and his lab are researching the connection between tissue damage and disease progression through the study of DNA. This new method has the potential to be applied to earlier detection of multiple types of cancer, type 1 diabetes, as well as the evaluation of tissue damage following a traumatic brain injury or stroke.
November 21, 2016
The Fall 2016 issue of the Partners Biobank newsletter for Biobank participants has been released.
September 6, 2016
Drs. I-Cheng Ho and Hui-Hsin Chang of Brigham and Women’s Hospital recently published a paper in Arthritis & Rheumatology on the results of a study they completed using samples from the Partners Biobank. This study investigated the relationship between a variation in a gene and the risk for the development of rheumatoid arthritis (RA). Drs. Ho and Chang found that the variation in this gene leads to increased activity of immune cells, which can cause the inflammation characteristic of RA.